GENENTA SCIENCE S.P.A.

Genenta Progresses to Higher Dosing Cohort in Temferon™ Phase 1/2a Clinical Trial in Glioblastoma Multiforme

04 5 2022 07:30:00 提供 Nasdaq GlobeNewswire

Genenta Announces Nomination of Mark A. Sirgo as Chair

27 4 2022 07:30:00 提供 Nasdaq GlobeNewswire

Genenta to Host Expert Fireside Chat on Immuno Gene & Cell Therapy for Treatment of Solid Tumors

20 4 2022 07:30:00 提供 Nasdaq GlobeNewswire

Genenta Data Presentation at AACR to Describe On-Target Biological Activity of Temferon™ in Unmethylated Glioblastoma Multiforme

09 3 2022 07:46:22 提供 Nasdaq GlobeNewswire

Genenta to Participate at Upcoming Investor Conferences

24 2 2022 07:30:01 提供 Nasdaq GlobeNewswire

Genenta Closes Its Upsized Initial Public Offering of American Depository Shares

17 12 2021 16:15:00 提供 Nasdaq GlobeNewswire

Genenta Announces Pricing of Upsized Initial Public Offering

14 12 2021 22:36:29 提供 Nasdaq GlobeNewswire